Partner-funded engine with retained assets
Isomorphic Labs
This split model is how an AI drug company pays for an expensive engine without giving away the upside. Lilly, Novartis, and J&J collaborations bring cash, targets, assays, and a public signal that large pharma is willing to trust the system on real programs. Internal oncology and immunology assets matter more economically, because if a designed molecule works, Isomorphic can keep far more of the milestone, licensing, or end market value.
-
The partner side already has real economic weight. The 2024 Lilly and Novartis deals alone carried nearly $3B in potential value, with $45M upfront from Lilly and $37.5M upfront from Novartis. Novartis then expanded from three programs to six after about a year, which is strong external validation.
-
The internal side is funded to run longer. Isomorphic disclosed about $2.7B of external funding, made up of a $600M round in March 2025 and a $2.1B Series B in May 2026, giving it enough capital to push owned assets toward the clinic instead of licensing them out as soon as they look promising.
-
This is the same broad playbook used by other AI biotechs, but with more capital behind it. Genesis also mixes partner funded discovery with owned programs, while Xaira is building a vertically integrated platform with about $1B in funding. The difference is that Isomorphic has unusually large balance sheet support for both channels at once.
The next step is a shift from being judged by partnership signings to being judged by owned pipeline progress. As internal candidates move into IND enabling work and eventually the clinic, the company has a chance to convert pharma validation into biotech style value capture, with much larger returns per successful asset.